Cumberland Pharmaceuticals Inc CPIX
Cumberland Pharmaceuticals Inc (Nasdaq: CPIX) is a rare genetic drug developer. Its lead program, ifetroban, is in Phase 2 for cardiomyopathy associated with Duchenne muscular dystrophy (also SSc, IPF, cancer metastasis). Its next catalyst on record is ifetroban (SSc): Top-line results (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ifetroban (SSc) — Top-line results (date not stated). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ifetroban (DMD cardiomyopathy) | Duchenne muscular dystrophy cardiomyopathy | small molecule | Phase 2 |
| ifetroban (systemic sclerosis) | Systemic sclerosis | small molecule | Phase 2 |
| ifetroban (idiopathic pulmonary fibrosis) | IPF | small molecule | Phase 2 |
| ifetroban (cancer metastasis prevention) | high-risk solid tumors | small molecule | Phase 2 |
| CET delirium candidate | hospitalized patient delirium | unclear | Pre-clinical |
Recent results and decisions
- Aug 4, 2026met Randomized Phase 2 (Vanderbilt) met its primary safety/feasibility objective; metastatic recurrence 3/18 (17%) on ifetroban vs 5/10 (50%) on placebo (OR 0.21, p=0.09, not significant); distant-metastasis deaths 0/18 vs 3/10 (p=0.037).
The study met its primary objective of assessing safety and feasibility.
Filing - Jul 1, 2026positive Vanderbilt-collaboration Phase 2 pilot showed ifetroban safe and well tolerated with a favorable trend toward fewer deaths from metastatic disease vs placebo; no numbers in this release.
The findings suggests the potential to block cancer metastasis, as a favorable trend was identified with fewer deaths due to metastatic disease in those receiving ifetroban rather than a placebo.
Filing - Feb 4, 2026n/a FDA granted Fast Track Designation to ifetroban for DMD heart disease, following Orphan Drug and Rare Pediatric Disease designations (designation, not an approval or hold decision).
announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy ("DMD") patients.
Filing
3 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.